Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carmustine polifeprosan 20 wafer - Arbor Pharmaceuticals/ Eisai

Next Previous
X
Search
Drug Profile

Carmustine polifeprosan 20 wafer - Arbor Pharmaceuticals/ Eisai

Alternative Names: BCNU; BIODEL carmustine; Carmustine BIODEL; Gliadel; Gliadel® Wafer; NPC-08; NSC-409962; WR-139021

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer Arbor Pharmaceuticals; Eisai Co Ltd; Nobelpharma; Orphan Australia
  • Class Antineoplastics; Nitrosourea compounds; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glioma

Most Recent Events

  • 02 Sep 2015 The Japanese MHLW lifts the all-case surveillance condition required for the approval of Gliadel® for the treatment of Glioma
  • 24 Apr 2015 Launched for Glioma in Mexico (Intracerebral)
  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top